NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

Not Yet RecruitingPhase 2

Sponsor: Novartis Pharmaceuticals

Conditions: Primary Immune Thrombocytopenia (ITP)

Interventions: Ianalumab, Eltrombopag

The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to \<18 years of age) with primary ITP who have had an insufficient response to or relapsed after first-line treatment with corticosteroids.

Eligibility overview

Sex: ALL

Age: 5 Years to 17 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Signed informed consent and/or assent must be obtained from the participant and/or their parent(s)/legal guardian(s) before any study-related activity or assessment is performed. Informed consent must be obtained from participants once they reach the local legal age of adulthood during the study.
* Male or female patients aged 5 to \<18 years on the day of signing informed assent/consent (as appropriate for age).
* A confirmed diagnosis of primary ITP, with insufficient response to, or relapse after a firstline corticosteroid therapy with or without IVIG.
* Patients with platelet count \<30 G/L for whom eltrombopag is clinically indicated (per physician's discretion) and with no contraindications to receive eltrombopag.
* Patients who are up-to-date on childhood vaccinations as per the local recommended vaccination schedule.

Exclusion Criteria:

* Patients with ITP who received previous second-line ITP treatments (other than corticosteroid therapy with or without IVIG) including splenectomy. However, patients exposed to thrombopoietin receptor agonists (TPO-RAs) for a limited time (maximum one week) before or during screening are eligible.
* Patients with key renal or hepatic laboratory abnormalities.
* Patients with other hematologic diagnosis associated with cytopenias, including Evans Syndrome.
* Patients with current or history of life-threatening bleeding due to thrombocytopenia.
* Patients who are Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) positive.
* Patients with known active or uncontrolled infections requiring systemic treatment during the screening period or history of recurrent clinically significant infection.
* Patients with hepatic impairment (Child-Pugh score \>5, or equivalent).
* Patients with concurrent bleeding disorders or coagulation disorders and/or receiving antiplatelet or anticoagulant medication.
* Female patients who are nursing or pregnant.

Other protocol-defined inclusion/exclusion may apply.